BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi JH, Jonsson-Schmunk K, Qiu X, Shedlock DJ, Strong J, Xu JX, Michie KL, Audet J, Fernando L, Myers MJ, Weiner D, Bajrovic I, Tran LQ, Wong G, Bello A, Kobinger GP, Schafer SC, Croyle MA. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Mol Pharm 2015;12:2712-31. [PMID: 25363619 DOI: 10.1021/mp500646d] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Cross RW, Mire CE, Feldmann H, Geisbert TW. Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discov 2018;17:413-34. [DOI: 10.1038/nrd.2017.251] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 14.3] [Reference Citation Analysis]
2 Ji Z, Xie Z, Wang Q, Zhang Z, Gong T, Sun X. A Prime-Boost Strategy Combining Intravaginal and Intramuscular Administration of Homologous Adenovirus to Enhance Immune Response Against HIV-1 in Mice. Hum Gene Ther 2016;27:219-29. [PMID: 26715124 DOI: 10.1089/hum.2015.153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sulaiman KO, Kolapo TU, Onawole AT, Islam MA, Adegoke RO, Badmus SO. Molecular dynamics and combined docking studies for the identification of Zaire ebola virus inhibitors. J Biomol Struct Dyn 2019;37:3029-40. [PMID: 30058446 DOI: 10.1080/07391102.2018.1506362] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
4 Onawole AT, Kolapo TU, Sulaiman KO, Adegoke RO. Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring. Comput Biol Chem 2018;72:170-80. [PMID: 29361403 DOI: 10.1016/j.compbiolchem.2017.11.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
5 Bajrovic I, Le MD, Davis MM, Croyle MA. Evaluation of intermolecular interactions required for thermostability of a recombinant adenovirus within a film matrix. J Control Release 2021;341:118-31. [PMID: 34780881 DOI: 10.1016/j.jconrel.2021.11.012] [Reference Citation Analysis]
6 Reynolds P, Marzi A. Ebola and Marburg virus vaccines. Virus Genes 2017;53:501-15. [PMID: 28447193 DOI: 10.1007/s11262-017-1455-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 8.6] [Reference Citation Analysis]
7 Jonsson-Schmunk K, Croyle MA. A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact. Expert Rev Anti Infect Ther 2015;13:527-30. [PMID: 25796987 DOI: 10.1586/14787210.2015.1028368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
8 Kaushik A, Tiwari S, Dev Jayant R, Marty A, Nair M. Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosens Bioelectron 2016;75:254-72. [PMID: 26319169 DOI: 10.1016/j.bios.2015.08.040] [Cited by in Crossref: 94] [Cited by in F6Publishing: 73] [Article Influence: 13.4] [Reference Citation Analysis]
9 Wong G, Mendoza EJ, Plummer FA, Gao GF, Kobinger GP, Qiu X. From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther 2018;18:159-73. [PMID: 29148858 DOI: 10.1080/14712598.2018.1404572] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
10 Liu G, Nash PJ, Johnson B, Pietzsch C, Ilagan MX, Bukreyev A, Basler CF, Bowlin TL, Moir DT, Leung DW, Amarasinghe GK. A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface. ACS Infect Dis 2017;3:190-8. [PMID: 28152588 DOI: 10.1021/acsinfecdis.6b00209] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
11 Jonsson-Schmunk K, Ghose R, Croyle MA. Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A. Expert Rev Vaccines 2021;20:623-34. [PMID: 33666138 DOI: 10.1080/14760584.2021.1899818] [Reference Citation Analysis]
12 Wang T, Yin H, Li Y, Zhao L, Sun X, Cong H. Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes. Parasite 2017;24:12. [PMID: 28367800 DOI: 10.1051/parasite/2017013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
13 Feng Y, Li C, Hu P, Wang Q, Zheng X, Zhao Y, Shi Y, Yang S, Yi C, Feng Y, Wu C, Qu L, Xu W, Li Y, Sun C, Gao FG, Xia X, Feng L, Chen L. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerg Microbes Infect 2018;7:101. [PMID: 29872043 DOI: 10.1038/s41426-018-0102-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
14 Wu S, Kroeker A, Wong G, He S, Hou L, Audet J, Wei H, Zhang Z, Fernando L, Soule G, Tran K, Bi S, Zhu T, Yu X, Chen W, Qiu X. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. J Infect Dis 2016;214:S326-32. [PMID: 27493239 DOI: 10.1093/infdis/jiw250] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
15 Wong G, Richardson JS, Pillet S, Racine T, Patel A, Soule G, Ennis J, Turner J, Qiu X, Kobinger GP. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates. J Infect Dis 2015;212 Suppl 2:S379-83. [PMID: 25957963 DOI: 10.1093/infdis/jiv102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
16 Choi JH, Schafer SC, Freiberg AN, Croyle MA. Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine. Mol Pharm 2015;12:2697-711. [PMID: 25549696 DOI: 10.1021/mp5006454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
17 Ran H, Quan G, Huang Y, Zhu C, Lu C, Liu W, Pan X, Wu C. The practical self-targeted oncolytic adenoviral nanosphere based on immuno-obstruction method via polyprotein surface precipitation technique enhances transfection efficiency for virotherapy. Biochem Biophys Res Commun 2019;508:791-6. [PMID: 30528388 DOI: 10.1016/j.bbrc.2018.10.162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines 2015;3:125-38. [PMID: 26668751 DOI: 10.1177/2051013615611017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
19 Lázaro-Frías A, Gómez-Medina S, Sánchez-Sampedro L, Ljungberg K, Ustav M, Liljeström P, Muñoz-Fontela C, Esteban M, García-Arriaza J. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. J Virol 2018;92:e00363-18. [PMID: 29514907 DOI: 10.1128/JVI.00363-18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
20 Yin H, Zhao L, Wang T, Zhou H, He S, Cong H. A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection. Parasit Vectors 2015;8:498. [PMID: 26420606 DOI: 10.1186/s13071-015-1108-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
21 Wong G, Richardson JS, Cutts T, Qiu X, Kobinger GP. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Res 2015;116:17-9. [PMID: 25596432 DOI: 10.1016/j.antiviral.2015.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
22 Ohimain EI. Recent advances in the development of vaccines for Ebola virus disease. Virus Res 2016;211:174-85. [PMID: 26596227 DOI: 10.1016/j.virusres.2015.10.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
23 Bajrovic I, Schafer SC, Romanovicz DK, Croyle MA. Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature. Sci Adv 2020;6:eaau4819. [PMID: 32181330 DOI: 10.1126/sciadv.aau4819] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
24 Guito JC, Albariño CG, Chakrabarti AK, Towner JS. Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system. Virology 2017;501:147-65. [PMID: 27930961 DOI: 10.1016/j.virol.2016.11.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
25 Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines 2016;15:1101-12. [PMID: 27160784 DOI: 10.1080/14760584.2016.1187566] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
26 Gomi R, Sharma A, Wu W, Sung B, Worgall S. Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection. Vaccine 2017;35:7174-80. [PMID: 29126807 DOI: 10.1016/j.vaccine.2017.10.078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Graveline R, Haida M, Dumont C, Poulin D, Poitout-Belissent F, Samadfam R, Kronenberg S, Regenass-Lechner F, Prell R, Piche MS. Development of a nonhuman primate challenge model to evaluate CD8+ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors. MAbs 2022;14:1979447. [PMID: 34923919 DOI: 10.1080/19420862.2021.1979447] [Reference Citation Analysis]